PURPOSE: Primary plasma cell leukemia (pPCL) is a rare and very aggressive form of plasma cell dyscrasia. To date, no information on miRNA expression in pPCL has been reported. This study was aimed at investigating the involvement of miRNAs in pPCL and their possible relationship with higher tumor aggressiveness. Experimental design: Global miRNA expression profiles were analyzed in highly-purified malignant plasma cells from 18 pPCL untreated patients included in a prospective clinical trial. MiRNA expression patterns were evaluated in comparison with a representative series of multiple myeloma (MM) patients, in relation to the most recurrent chromosomal abnormalities (as assessed by fluorescence in situ hybridization and single nucleotide polymorphism-array analysis), and in association with clinical outcome. MiRNA expression was also integrated with gene expression profiles in pPCL and MM samples. RESULTS: We identified a series of deregulated miRNAs in pPCL (42 up- and 41 down-regulated) in comparison with MM. Some of them, based on their reported functions and putative target genes computed by integrative analysis, might have a role in the pathobiology of pPCL. As regards to chromosomal aberrations, the expression of some miRNAs mapped to hot-spot altered regions was associated with DNA copy number of the corresponding loci. Finally, four miRNA (miR-497, miR-106b, miR-181a* and miR-181b) were identified having expression levels correlated with treatment response, and four (miR-92a, miR-330-3p, miR-22, and miR-146a) with clinical outcome. CONCLUSIONS: Overall, our study provides insights into the possible contribution of miRNAs in the pathogenesis of pPCL and suggests targets for future therapeutic investigations

Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia / M. Lionetti, P. Musto, M.T. Di Martino, S. Fabris, L. Agnelli, K. Todoerti, G. Tuana, L. Mosca, M.E. Gallo Cantafio, V. Grieco, G. Bianchino, F. D'Auria, T. Statuto, C. Mazzoccoli, L. De Luca, M.T. Petrucci, M. Offidani, F. Di Raimondo, A. Falcone, T. Caravita, P. Omede, F. Morabito, P. Tassone, M. Boccadoro, A. Palumbo, A. Neri. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - 19:12(2013 Apr 23), pp. 3130-3142. [10.1158/1078-0432.CCR-12-2043]

Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia

M. Lionetti
Primo
;
S. Fabris;L. Agnelli;K. Todoerti;L. Mosca;A. Neri
Ultimo
2013

Abstract

PURPOSE: Primary plasma cell leukemia (pPCL) is a rare and very aggressive form of plasma cell dyscrasia. To date, no information on miRNA expression in pPCL has been reported. This study was aimed at investigating the involvement of miRNAs in pPCL and their possible relationship with higher tumor aggressiveness. Experimental design: Global miRNA expression profiles were analyzed in highly-purified malignant plasma cells from 18 pPCL untreated patients included in a prospective clinical trial. MiRNA expression patterns were evaluated in comparison with a representative series of multiple myeloma (MM) patients, in relation to the most recurrent chromosomal abnormalities (as assessed by fluorescence in situ hybridization and single nucleotide polymorphism-array analysis), and in association with clinical outcome. MiRNA expression was also integrated with gene expression profiles in pPCL and MM samples. RESULTS: We identified a series of deregulated miRNAs in pPCL (42 up- and 41 down-regulated) in comparison with MM. Some of them, based on their reported functions and putative target genes computed by integrative analysis, might have a role in the pathobiology of pPCL. As regards to chromosomal aberrations, the expression of some miRNAs mapped to hot-spot altered regions was associated with DNA copy number of the corresponding loci. Finally, four miRNA (miR-497, miR-106b, miR-181a* and miR-181b) were identified having expression levels correlated with treatment response, and four (miR-92a, miR-330-3p, miR-22, and miR-146a) with clinical outcome. CONCLUSIONS: Overall, our study provides insights into the possible contribution of miRNAs in the pathogenesis of pPCL and suggests targets for future therapeutic investigations
Settore MED/15 - Malattie del Sangue
Article (author)
File in questo prodotto:
File Dimensione Formato  
Lionetti_CCR_2013_miRNAs_pPCL.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.13 MB
Formato Adobe PDF
1.13 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/219850
Citazioni
  • ???jsp.display-item.citation.pmc??? 53
  • Scopus 79
  • ???jsp.display-item.citation.isi??? 80
social impact